Director at Standard BioTools (LAB) takes RSUs instead of cash pay
Rhea-AI Filing Summary
Cox Troy reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on
The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.
Positive
- None.
Negative
- None.
FAQ
What did Troy Cox report in his latest Form 4 for LAB?
Troy Cox reported receiving 57,264 restricted stock units representing common stock of STANDARD BIOTOOLS INC. (LAB). The grant reflects equity compensation for his board service and increases his directly held stake to 376,586 shares after the award.
How do Troy Cox’s new RSUs for LAB vest over time?
The 57,264 RSUs granted to Troy Cox vest in four equal 25% installments during 2026. Vesting occurs on the last day of the last month of each fiscal quarter, provided he continues serving on the board through each applicable vesting date.
Why did Troy Cox receive RSUs instead of cash from STANDARD BIOTOOLS (LAB)?
Troy Cox elected to receive RSUs in lieu of $67,000 in cash compensation for his board services. This choice shifts his compensation toward equity, further aligning his interests with shareholders through additional stock-based incentives rather than immediate cash payment.
What is Troy Cox’s total LAB share ownership after this Form 4 transaction?
After the reported RSU grant, Troy Cox directly holds 376,586 shares of STANDARD BIOTOOLS INC. common stock. This figure includes the newly awarded 57,264 RSUs, which vest over 2026 subject to his continued service on the company’s board.
At what price were Troy Cox’s new LAB RSUs reported for valuation purposes?
The 57,264 RSUs granted to Troy Cox were reported at $1.17 per share for valuation purposes. This price is used solely for disclosure and accounting in the Form 4, reflecting the reference value of the equity-based compensation award.